L3VLUP
ProSign in

MDGL · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MDGLVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MDGL
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterMDGLVRTX
Q3 20203 holders, $311m31 holders, $21.9bn
Q4 20202 holders, $234m30 holders, $18.4bn
Q1 20214 holders, $281m31 holders, $15.4bn
Q2 20212 holders, $67m30 holders, $12.7bn
Q3 20211 holders, $18m35 holders, $10.1bn
Q4 20211 holders, $19m28 holders, $12.4bn
Q1 20221 holders, $22m23 holders, $16.1bn
Q2 20222 holders, $21m25 holders, $18.1bn
Q3 20222 holders, $14m22 holders, $18.4bn
Q4 20224 holders, $204m28 holders, $18.4bn
Q1 20239 holders, $384m26 holders, $21.4bn
Q2 20235 holders, $589m27 holders, $24.7bn
Q3 20236 holders, $579m33 holders, $24.3bn
Q4 20235 holders, $820m32 holders, $28.6bn
Q1 20248 holders, $1.1bn31 holders, $29.8bn
Q2 20247 holders, $1.1bn29 holders, $33.4bn
Q3 20246 holders, $788m27 holders, $33.5bn
Q4 20246 holders, $1.1bn26 holders, $28.5bn
Q1 20257 holders, $1.2bn21 holders, $35.4bn
Q2 20256 holders, $961m21 holders, $32.3bn
Q3 20259 holders, $1.3bn22 holders, $25.9bn
Q4 202512 holders, $1.8bn26 holders, $31.8bn
Q1 202610 holders, $2.2bn25 holders, $31.8bn
Q2 202611 holders, $2.3bn26 holders, $34.6bn
MDGL

Madrigal Pharmaceuticals Inc

Holders
5
Reported value
$820m
Buyers
2
Sellers
2

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MDGL (0)

None.

Only VRTX (27)

Acadian Asset Management LLC, AQR Capital Management LLC, ARK Investment Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →